Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 2/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.33 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497582 | 1.00 | SHBG (0.35) | SHBGGPBAR1NR3C1CYP19A1NR1H4 | |
| SCHEMBL4438158 | 1.00 | SHBG (0.35) | SHBGGPBAR1NR3C1CYP19A1NR1H4 | |
| SCHEMBL6000815 | 0.86 | SHBG (0.47) | SHBGGPBAR1CYP19A1ESR1ESR2 | |
| SCHEMBL6446959 | 0.82 | GPBAR1 (0.43) | SHBGGPBAR1NR3C1CYP19A1AR | |
| SCHEMBL6434159 | 0.82 | GPBAR1 (0.43) | SHBGGPBAR1NR3C1CYP19A1AR | |
| SCHEMBL497888 | 0.82 | GPBAR1 (0.43) | SHBGGPBAR1NR3C1CYP19A1AR | |
| SCHEMBL497753 | 0.81 | GPBAR1 (0.34) | SHBGGPBAR1NR3C1CYP19A1NR1H4 | |
| SCHEMBL5524700 | 0.81 | GPBAR1 (0.34) | SHBGGPBAR1NR3C1CYP19A1NR1H4 | |
| SCHEMBL497527 | 0.81 | G6PD (0.46) | SHBGGPBAR1NR3C1CYP19A1SLC10A1 | |
| SCHEMBL5488565 | 0.81 | G6PD (0.46) | SHBGGPBAR1NR3C1CYP19A1SLC10A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097406-A1 | Pharmaceutical compositions and treatment methods - 4 | BIOVIE INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097406-A1 | Pharmaceutical compositions and treatment methods - 4 | HSD3B1, IL4, HSD17B7 | SHBG 44/4885GPBAR1 313/4885NR3C1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.